Elevated levels of tenascin-C in patients with cryptogenic organizing pneumonia

Internal Medicine

Volumn 48, Issue 17, 2009, Pages 1501-1507

  Hisatomi, Keiko ^a   Sakamoto, Noriho ^a   Mukae, Hiroshi ^a   Hayashi, Tomayoshi ^b   Amenomori, Misato ^a   Ishimoto, Hiroshi ^a   Fujita, Hanako ^a   Ishii, Hiroshi ^c   Nakayama, Seiko ^b   Ishimatsu, Yuji ^a   Kohno, Shigeru ^a  

^a NAGASAKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b NAGASAKI UNIVERSITY HOSPITAL   (Japan)

^c OITA UNIVERSITY   (Japan)

Author keywords

Bronchial inflammation; Diffuse parenchymal lung diseases; Extracellular matrix; Idiopathic interstitial pneumonias; Idiopathic pulmonary fibrosis

Indexed keywords

C REACTIVE PROTEIN; CD4 ANTIGEN; CD8 ANTIGEN; TENASCIN;

ADULT; AGED; ARTERIAL OXYGEN TENSION; ARTICLE; CD4 CD8 RATIO; CLINICAL ARTICLE; EOSINOPHIL COUNT; EXTRACELLULAR MATRIX; FEMALE; FIBROSING ALVEOLITIS; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; INFLAMMATION; INTERSTITIAL PNEUMONIA; LACTATE DEHYDROGENASE BLOOD LEVEL; LEUKOCYTE COUNT; LUNG ALVEOLUS MACROPHAGE; LUNG LAVAGE; LYMPHOCYTE COUNT; MALE; NEUTROPHIL COUNT; NONSPECIFIC INTERSTITIAL PNEUMONIA; ORGANIZING PNEUMONIA; PATHOGENESIS; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN FUNCTION;

ADULT; AGED; BIOLOGICAL MARKERS; BRONCHOALVEOLAR LAVAGE FLUID; CRYPTOGENIC ORGANIZING PNEUMONIA; FEMALE; HUMANS; IDIOPATHIC INTERSTITIAL PNEUMONIAS; INFLAMMATION MEDIATORS; MALE; MIDDLE AGED; TENASCIN;

EID: 70349492525     PISSN: 09182918     EISSN: 13497235     Source Type: Journal    
DOI: 10.2169/internalmedicine.48.2233     Document Type: Article

References (20)

1. Kim DS, Collard HR, King TE Jr. Classification and natural history of the idiopathic interstitial pneumonias. Proc Am Thorac Soc 3: 285-292, 2006.
2. American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias. This joint statement of the American Thoracic Society (ATS), and the European Respiratory Society (ERS) was adopted by the ATS board of directors, June 2001 and by the ERS Executive Committee, June 2001. Am J Respir Crit Care Med 165: 277-304, 2002.
3. Pardo A, Selman M. Matrix metalloproteases in aberrant fibrotic tissue remodeling. Proc Am Thorac Soc 3: 383-388, 2006.
4. Chiquet-Ehrismann R, Chiquet M. Tenascins: regulation and putative functions during pathological stress. J Pathol 200: 488-499, 2003.
5. Chiquet-Ehrismann R, Tucker RP. Connective tissues: signalling by tenascins. Int J Biochem Cell Biol 36: 1085-1089, 2004.
6. Jones FS, Jones PL. The tenascin family of ECM glycoproteins: structure, function, and regulation during embryonic development and tissue remodeling. Dev Dyn 218: 235-259, 2000.
7. Jones PL, Jones FS. Tenascin-C in development and disease: gene regulation and cell function. Matrix Biol 19: 581-596, 2000.
8. Kuhn C, Mason RJ. Immunolocalization of SPARC, tenascin, and thrombospondin in pulmonary fibrosis. Am J Pathol 147: 1759-1769, 1995.
9. Wallace WA, Howie SE, Lamb D, Salter DM. Tenascin immunoreactivity in cryptogenic fibrosing alveolitis. J Pathol 175: 415-420, 1995.
10. Kaarteenaho-Wiik R, Tani T, Sormunen R, Soini Y, Virtanen I, Paakko P. Tenascin immunoreactivity as a prognostic marker in usual interstitial pneumonia. Am J Respir Crit Care Med 154: 511-518, 1996.
11. Kaarteenaho-Wiik R, Mertaniemi P, Sajanti E, Soini Y, Paakko P. Tenascin is increased in epithelial lining fluid in fibrotic lung disorders. Lung 176: 371-380, 1998.
12. Paakko P, Kaarteenaho-Wiik R, Pollanen R, Soini Y. Tenascin mRNA expression at the foci of recent injury in usual interstitial pneumonia. Am J Respir Crit Care Med 161: 967-972, 2000.
13. Ishii H, Mukae H, Kadota J, et al. High serum concentrations of surfactant protein A in usual interstitial pneumonia compared with non-specific interstitial pneumonia. Thorax 58: 52-57, 2003.
14. Sakamoto N, Mukae H, Fujii T, et al. Soluble form of Fas and Fas ligand in serum and bronchoalveolar lavage fluid of individuals infected with human T-lymphotropic virus type 1. Respir Med 98: 213-219, 2004.
15. Kaarteenaho-Wiik R, Sademies O, Paakko P, Risteli J, Soini Y. Extracellular matrix proteins and myofibroblasts in granulomas of sarcoidosis, atypical mycobacteriosis, and tuberculosis of the lung. Hum Pathol 38: 147-153, 2007.
16. Zhao Y, Young SL, McIntosh JC. Induction of tenascin in rat lungs undergoing bleomycin-induced pulmonary fibrosis. Am J Physiol 274: L1049-1057, 1998.
17. Amin K, Ludviksdottir D, Janson C, et al. Inflammation and structural changes in the airways of patients with atopic and nonatopic asthma. BHR Group. Am J Respir Crit Care Med 162: 2295-2301, 2000.
18. Amin K, Ekberg-Jansson A, Lofdahl CG, Venge P. Relationship between inflammatory cells and structural changes in the lungs of asymptomatic and never smokers: a biopsy study. Thorax 58: 135-142, 2003.
19. Clark RA, Erickson HP, Springer TA. Tenascin supports lymphocyte rolling. J Cell Biol 137: 755-765, 1997.
20. Lopez-Moratalla N, del Mar, Calonge M, Lopez-Zabalza MJ, Perez-Mediavilla LA, Subira ML, Santiago E. Activation of human lymphomononuclear cells by peptides derived from extracellular matrix proteins. Biochim Biophys Acta 1265: 181-188, 1995.